Summary:
A Phase III randomized, open-label, comparative trial comparing the incidence of hypophosphatemia in relation to treatment with iron isomaltoside and ferric carboxymaltose in subjects with iron deficiency anemia.
Qualified Participants Must:
• Be aged 18 years of age or older
•
Have IDA caused by different aetiologies such as ab-normal uterine bleeding, gastrointestinal diseases, cancer, bariatric procedures (gastric bypass operations), and other conditions leading to significant blood loss
•
Have history of intolerance or unresponsiveness to oral iron therapy
Qualified Participants May Receive:
Compensation for their time and travel as well as all eligible participants will receive study treatment and medication at no cost.